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Abstract The application of nanomaterial in cancer treat-
ment is promising and intriguing. Anti-tumor immunother-
apy has the potential to significantly improve the prognosis
of cancer treatment, though the efficacy of immunotherapy
generally needs further improvement. One way to improve
the efficacy is using immune adjuvants, but the adjuvants for
anticancer immunotherapy have to be more potent than for
prophylactic vaccines. Here, we report that compared to
conventional alum adjuvant, aluminum oxide nanoparticles
(nano-alum) may further enhance the anticancer effects of an
immunotherapy that employs tumor cell vaccine (TCV). The
average tumor size tends to be lower in animals that receive
the combinational treatment of nano-alum and TCV. The
anticancer cytotoxicity by the lymphocytes was also signif-
icantly higher in the treatment group that received both TCV
and nano-alum. These results suggest that nano-alum may
potentially serve as a potent immune adjuvant and have
prospective applications in anticancer immunotherapy.
Keywords Aluminum . Nanoparticle . Anticancer .
Immune adjuvant
1 Introduction
Nanotechnology may have important applications in mul-
tiple biomedical fields (Williams et al. 2002; Heller et al.
2006; Elder et al. 2008; Jain 2008; Cai et al. 2005; Fenske
and Cullis 2008; Bianco et al. 2005a; Martin and Kohli
2003; Liu et al. 2005; Ni et al. 2005; Sun et al. 2002;
Zanello et al. 2006; Bianco et al. 2005b; Hartman et al.
2008), and the use of nanomaterial in cancer treatment is
particularly intriguing (Fifis et al. 2004; Farokhzad et al.
2006). One important issue in cancer immunology is the
search of novel immune adjuvants that can enhance the
efficacy of anti-tumor immunotherapy (Mesa and Fernandez
2004). Immunotherapy is an important form of adjunctive
cancer treatment that may significantly improve the prognosis
(Vermorken et al. 1999; Schirrmacher 2005; Takayama et al.
2000). Prior clinical trials of immunotherapy have achieved
promising results in treating malignancies such as melanoma,
malignant glioma, or renal cell carcinoma (Berd et al. 2004;
Yu et al. 2004; Rosenberg et al. 1994), which tend to respond
poorly to chemotherapies. Nevertheless, the efficacy of
current anticancer immunotherapy generally needs further
improvement (Emens 2006). Because tumor antigens are
usually self-derived and are, therefore, poorly immunogenic,
the adjuvants for anticancer immunotherapy have to be more
Zhao Sun and Wei Wang contributed equally to this paper.
Z. Sun :X. Lu : Z. Zhu : S. Chen
Peking Union Medical College Hospital,
Beijing 100730, China
W. Wang : J. Duan :Y. Hu : J. Ma : J. Zhou :H. Xu (*) :
X.-D. Yang (*)
Institute of Basic Medical Sciences,
Chinese Academy of Medical Sciences,
Beijing 100005, China
e-mail: xuhy@pumc.edu.cn
e-mail: ayangmd@gmail.com
R. Wang : C. Wang (*)
National Center of Nanoscience and Technology,
Beijing 100080, China
e-mail: wangch@iccas.ac.cn
S. Xie
Institute of Physics, Chinese Academy of Sciences,
Beijing 100080, China
Y. Zhao
Beijing TianTan Hospital,
Beijing 100050, China
Cancer Nano (2010) 1:63–69
DOI 10.1007/s12645-010-0001-5
potent than for prophylactic vaccines (Mesa and Fernandez
2004). One way to increase the efficacy is using immune
adjuvants, which are defined as products that increase the
immune response toward antigens. The identification of
novel and more efficacious adjuvants is thus of practical
importance for anticancer immunotherapy (Mesa and
Fernandez 2004; Emens 2006).
Aluminum nanoparticle (nano-alum) may serve as a
candidate of prospective adjuvant for anticancer immuno-
therapy, which needs to be both safe and efficacious. Alum
(aluminum hydroxide, phosphate, or hydroxyphosphate)
has an excellent safety record for systemic vaccination. It
has been used as adjuvant for more than 60 years and is at
present the most widely used adjuvant in both veterinary
and human vaccines (Mesa and Fernandez 2004; Lindblad
2004). However, alum is mostly a Th2 stimulator of the
immune system and primarily enhances the antibody-
mediated reaction (Lindblad 2004). It has limited influence
on the cytotoxic T cell-mediated response, which is
considered the main mechanism of anticancer immune
effects (Mesa and Fernandez 2004; Berd et al. 2004;
Lindblad 2004). Since nanosized materials often exhibit
unique properties that may offer significant advantage for
biomedical applications (Jain 2008; Martin and Kohli
2003), it is sensible to investigate if nano-alum will be
more efficacious in enhancing anticancer immune response
than conventional alum. Here, we studied whether nano-
alum would influence the efficacy of an immunotherapy
that employs tumor cell vaccine (TCV), to evaluate nano-
alum’s applicability as an adjuvant in a commonly used
anticancer immune regimen.
2 Materials and methods
2.1 Compounds
Nano-alum (Al2O3, MW 101.96) was purchased from
Degussa Nanotechnology of Evonik Industries. Scanning
electron microscopy (SEM) was performed to evaluate the
size of the nanoparticles. Conventional alum in the form of
Al(OH)3 (analytical grade, MW 78.0) was purchased from
Beijing Chemical Reagents Company.
2.2 Animal
BALB/c mice were purchased from the Experimental
Animal Institute of the Chinese Academy of Medical
Sciences (Beijing, China), bred and maintained under
defined flora conditions in individually ventilated (high-
efficiency particle-arresting filtered air) sterile microisolator
cages (Techniplast, Milan, Italy). All animal handling and
experimental procedures were approved by the Animal
Care and Use Committee of the Chinese Academy of
Medical Sciences.
2.3 Preparations of alum or nano-alum adjuvants
Conventional alum in the form of Al(OH)3 was mixed with
D-Hanks solution at a concentration of 500 µg per ml
(6.4 mM/l) and fully sonicated, yielding a suspension ready
for further use. Nano-alum was mixed with D-Hanks
solution at the concentration of 326.9 µg per ml, to ensure
that the final molar concentration of nano-alum (6.4 mM/l)
is the same as that of the conventional alum adjuvant. The
nano-alum mixture was then sonicated immediately prior to
application, yielding a semi-clear solution ready for
immune studies.
2.4 Preparations of tumor cell vaccine
TCV was prepared by incubating H22 liver cancer cells in
D-Hanks solutioin containing Mitomycin C (80 mg/l) for
60 min, followed by thorough wash with D-Hanks for five
times.
2.5 Experiments of immunotherapy
Immunotherapy experiments were conducted using female
adult BALB/c mice, 8 weeks of age, weighing 18 to 22 g.
Twenty-eight mice were randomly divided into four groups:
(1) the control group, (2) the TCV treatment group, (3) the
TCV plus conventional alum (TCV+alum) treatment
group, and (4) the TCV plus nano-alum (TCV+nano-alum)
treatment group. On day zero, every mouse was inoculated
with 2×106 live H22 cells subcutaneously in the right hind
leg. On day 7 and 14, the treatment groups also received
two subcutaneous doses of designed immune treatment
agents in the left hind leg for triggering anti-tumor
reactions. Specifically, the TCV group received 2×106
TCV cells in 200 µl D-Hanks; the TCV+alum group
received 2×106 TCV cells in 100 µl D-Hanks mixed with
100 µl of alum adjuvant; and the TCV+nano-alum group
received 2×106 TCV cells in 100 µl D-Hanks mixed with
100 µl of nano-alum adjuvant. On day 7 and day 14, the
control group also received injections of 200 µl D-Hanks
that did not contain TCV or adjuvant. Tumor dimensions
were monitored using calipers at right angles every 3 to
4 days. The tumor size was measured using the product of
the two longest dimensions perpendicular to each other.
2.6 Immune cytotoxicity studies
Animals randomly picked from all groups were terminated
on day 30, and peripheral blood lymphocytes were
extracted and co-incubated with the H22 tumor cells. Ten
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thousand H22 tumor cells (target cells) were seeded on the
bottom of 96-well plates (Falcon) at a density of 2×108/L.
Periphery murine blood monocytes/lymphocytes (effector
cells) were obtained through standard Ficoll gradient
centrifugation. Effector cells (1×105 in 50 μL) were added
to the target cells, keeping the effector-to-target ratio at
10:1. The final combined volume per well was 100 μL.
Tissue culture plate was centrifuged at 250 rpm for 5 min to
ensure cell–cell contact, then incubated at 37°C with 5%
CO2 for 4 h. The lactate dehydrogenase (LDH) assay
reagents were added per manufacturer’s (Promega) instruc-
tion. The optical density of the supernatant was measured
using an ELISA plate reader with a 490 nm filter. The
values of effector cells’ spontaneous LDH release, target
cells’ spontaneous LDH release, target cells’ maximum
LDH release, and culture medium background reading were
also measured. The percentage of target cell killed was then
calculated per manufacturer’s protocol. The percent tumor
cell killed was calculated according to the following
equation:
% Cytotoxicity ¼ Experimental Effector spontaneous Target spontaneousð Þ  100
Target maximum  Target spontaneous
2.7 Histological studies of the tumor tissue
Tumor tissues were fixed and imbedded in paraffin. Tumor
sections of 5μmwere cut from the embedded tissue and stained
by standard hematoxylin and eosin procedure (HE stain), for
evaluation of tumor necrosis and lymphocyte infiltration.
2.8 Statistics
Statistical analysis was performed with the statistical SPSS
13.0 software. The nonparametric test was used to calculate
the probability of significant differences among the groups.
Statistical significance was defined as p<0.05.
3 Results
3.1 Characterization of the nano-alum
SEM of the nano-alum was carried out to evaluate the size of
the nanoparticles. The average diameter of the aluminum
nanoparticles was 20–30 nm (Fig. 1a and b). For immune
experiments, nano-alum adjuvant was freshly made through
mixing with D-Hanks solution, and sonicated immediately
prior to the injection, yielding semi-clear solution that was
stable and without precipitation for the entire duration of the
experiment.
3.2 Tumor size study
The animal study employed theH22murine hepatoma because
it was a mature tumor model that had been frequently used in
immunotherapy research (Luo et al. 2006). The outcome of
the immune treatment was assayed directly by the tumor size.
The individual tumor growth curve of each animal was
provided in Fig. 2a. After inoculation with H22 cells, most
animals gradually developed detectable subcutaneous tumor
mass in 5 to 10 days. In the control group, most tumors
steadily increased in size over the entire duration of the
experiment, whereas in the treatment groups, some tumors
tended to grow at slower rate. Moreover, in some animals
Fig. 1 Scanning electron mi-
croscopy images of the alumi-
num nanoparticle at low (a) and
high resolutions (b). The aver-
age particle size was about
20–30 nm
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that received treatments, the tumors stopped growing and
gradually shrank in size after about 20 days (Fig. 2a). The
averaged tumor size of each group was shown in Fig. 2b: all
the treatment groups tended to have lower average tumor size
than the control group, with the lowest average tumor size
belonging to the TCV+nano-alum group. On day 14, the
tumor size of the control group, the TCV group, the TCV+
alum group, and the TCV+nano-alum group was 31.71±
8.53 mm2, 15±2.88 mm2, 7.71±1.83 mm2, and 6.42±
2.22 mm2, respectively. On this day, both the TCV+alum
and the TCV+nano-alum groups had significantly smaller
average tumor size compared to the control group (p<0.05).
From day 18 to day 30, the differences in average tumor size
among the groups gradually became more prominent. On day
30, the tumor size was 91±22.69 mm2 for the control group,
61.27±27.63 mm2 for the TCV group, 72.28±26.05 mm2 for
the TCV+alum group, and 40.85±17.18 m2 for the TCV+
nano-alum group. The difference between the TCV+nano-
alum group and the control group was statistically significant
(p<0.05) on days 18, 22, 26, and 30, whereas none of the
Fig. 2 Tumor growth studies with
the tumor size measured every
4 days. a Individual tumor growth
curves of each experiment group. b
Average tumor size of each exper-
iment group (±SE, n=7 for each
group). The star indicates a statis-
tically significant difference (p<
0.05) from the control group
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other treatment groups showed a significant difference from
the control group. The results suggested that nano-alum
probably enhanced the anticancer reaction more efficiently,
resulting in the lower average tumor size observed in the
TCV+nano-alum group.
3.3 Immune cytotoxicity studies
To explore the mechanism of the improved outcome
observed in the treatment groups, cellular immunological
experiments were conducted. Specifically, the lympho-
cytes’ anti-tumor cytotoxicity was evaluated and compared
among the groups. Animals randomly picked from all
groups were terminated on day 30, and peripheral blood
lymphocytes were extracted and co-incubated with the H22
tumor cells. The cytotoxic effects of the lymphocytes
against the H22 cells were then measured using a standard
LDH assay. As shown in Fig. 3: the percentage of tumor
cell killed was 9.9±6.9 for the control group, 30.1±3.09
for the TCV group, 35.63±2.8 for the TCV+alum group,
and 67.96±9.54 for the TCV+nano-alum group. Thus, the
TCV+nano-alum group generated significantly higher
anticancer cytotoxicity compared to the other treatment
groups (p<0.05). The results suggested that nano-alum
had a more potent adjuvant effect than conventional alum,
and better enhanced the anti-tumor response induced by
TCV.
3.4 Histological studies of the tumor tissue
Histological studies of the tumor tissue were also
performed to evaluate the treatment outcome. The tumor
tissue of the control group was found relatively well
maintained with minimal lymphocyte infiltration
(Fig. 4a). In the treatment groups, however, the
tumor tissues were infiltrated with more lymphocytes
(Fig. 4b, c, d). Moreover, the tumor tissue of the TCV+
nano-alum group developed obvious necrosis (Fig. 4d),
suggesting that anti-tumor immune reaction was actively
in process.
Fig. 3 In vitro anti-tumor cytotoxicity studies. The lymphocytes’
cytotoxicity against the H22 tumor cells were measured using a
standard LDH assay at day 30 of the experiment. The most potent
anti-tumor cytotoxicity was observed in the TCV+nano-alum group
(*p<0.05, ±SE, n=6)
Fig. 4 Histological slides of the
tumor tissues stained with he-
matoxylin and eosin. a Control
group. b TCV group. c TCV+
alum group. d TCV+nano-alum
group. Lymphocyte infiltrations
were found in all the treatment
groups (b, c, d, arrowheads).
Tumor necrosis was observed in
the TCV+nano-alum group (d,
straight arrow)
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4 Discussion
The aim of this study was to investigate if nano-alum would
be a more potent adjuvant than conventional alum in an
anti-tumor immunotherapy employing TCV. The result
showed that nano-alum enhanced lymphocytes’ cytotox-
icity against the H22 liver cancer cells, whereas conven-
tional alum failed to generate a positive immune stimulating
effect (Fig. 3). The average tumor size in the TCV+nano-
alum group also tended to be lower (Fig. 2), presumably
because of the enhanced anti-tumor immune cytotoxicity in
this group. In addition, histological study also revealed
increased lymphocyte infiltration and tumor necrosis in the
TCV+nano-alum group (Fig. 4), again suggesting that
nano-alum boosted the anti-tumor response.
Frey et al. reported that aluminum nanoparticles chem-
ically conjugated to the C4 domain of the gp120 HIV
protein can generate relatively high antibody response
toward gp120 (Frey et al. 1999). Here, we showed that
nano-alum alone, without conjugation to antigen, could
enhance the TCV-induced anticancer immune response, and
that conventional alum failed to generate a similar effect
(Fig. 3). Both studies suggest that nano-alum is a more
potent immune adjuvant than conventional alum. This
presumably could be attributed to the unique physical and
chemical properties of nano-alum, which might be more
favorable for immune stimulation. It should be noted,
however, that the detailed mechanisms of both conventional
alum and nano-alum adjuvants remain to be unveiled to
date (Lindblad 2004), and much further research is still
warranted.
TCV was used in this study for triggering immune
response. TCV carries a mixture of tumor proteins and is
multivalent in terms of tumor antigens (Copier and
Dalgleish 2006). The major advantage of TCV is that it
may be applied in treatment of multiple malignancies,
irrespective of the genetic makeup of the cancer. However,
the lack of clearly defined tumor antigens in TCV therapy
renders the antibody responses difficult to assess. Because
the nature of the immunogens was not known, the efficacy of
TCV therapy was generally measured by tumor growth
retardation or prolonged survival, and not by antibody
production (Copier and Dalgleish 2006; Levy and Colombetti
2006). Nevertheless, some clinical studies based on such
vaccines have generated promising results (Vermorken et al.
1999; Schirrmacher 2005). In this study, nano-alum was
found to enhance the anti-tumor immunity induced by TCV.
Since TCV can often be made from surgically resected
tumors, nano-alum thus may have potential application in
immune treatment of multiple types of tumors that are
surgically accessible.
In summary, this study showed that nano-alum enhanced
the anticancer immune response induced by TCV. The
results suggest that nano-alum may potentially serve as an
effective adjuvant in anticancer immunotherapies.
Acknowledgment The authors thank Professors Hui Li and Yan
Shen of the Chinese Academy of Medical Sciences for insightful
suggestions. This work was made possible by the funding support
from the China Medical Board, the Ministry of Science and
Technology (2006CB933204), and Natural Science Foundation of
Beijing (Z0005190043511).
References
Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ (2004)
Immunopharmacologic analysis of an autologous, hapten-
modified human melanoma vaccine. J Clin Oncol 22:403–415
Bianco A, Kostarelos K, Partidos CD, Prato M (2005a) Biomedical
applications of functionalised carbon nanotubes. Chem Commun
(Camb) 5:571–577
Bianco A, Kostarelos K, Prato M (2005b) Applications of carbon
nanotubes in drug delivery. Curr Opin Chem Biol 9:674–679
Cai D, Mataraza JM, Qin ZH, Huang Z, Huang J, Chiles TC,
Carnahan D, Kempa K, Ren Z (2005) Highly efficient molecular
delivery into mammalian cells using carbon nanotube spearing.
Nat Methods 2:449–454
Copier J, Dalgleish A (2006) Overview of tumor cell-based vaccines.
Int Rev Immunol 25:297–319
Elder JB, Liu CY, Apuzzo ML (2008) Neurosurgery in the realm of 10
(-9), part 2: applications of nanotechnology to neurosurgery—
present and future. Neurosurgery 62:269–284, discussion 284-5
Emens LA (2006) Roadmap to a better therapeutic tumor vaccine. Int
Rev Immunol 25:415–443
Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW,
Richie JP, Langer R (2006) Targeted nanoparticle-aptamer
bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad
Sci U S A 103:6315–6320
Fenske DB, Cullis PR (2008) Liposomal nanomedicines. Expert Opin
Drug Deliv 5:25–44
Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram
PL, McKenzie IF, Plebanski M (2004) Size-dependent immuno-
genicity: therapeutic and protective properties of nano-vaccines
against tumors. J Immunol 173:3148–3154
Frey A, Mantis N, Kozlowski PA, Quayle AJ, Bajardi A, Perdomo JJ,
Robey FA, Neutra MR (1999) Immunization of mice with
peptomers covalently coupled to aluminum oxide nanoparticles.
Vaccine 17:3007–3019
Hartman KB, Wilson LJ, Rosenblum MG (2008) Detecting and
treating cancer with nanotechnology. Mol Diagn Ther 12:1–14
Heller DA, Jeng ES, Yeung TK, Martinez BM, Moll AE, Gastala JB,
Strano MS (2006) Optical detection of DNA conformational
polymorphism on single-walled carbon nanotubes. Science
311:508–511
Jain KK (2008) Nanomedicine: application of nanobiotechnology in
medical practice. Med Princ Pract 17:89–101
Levy F, Colombetti S (2006) Promises and limitations of murine
models in the development of anticancer T-cell vaccines. Int Rev
Immunol 25:269–295
Lindblad EB (2004) Aluminium adjuvants—in retrospect and pros-
pect. Vaccine 22:3658–3668
Liu Y, Wu DC, Zhang WD, Jiang X, He CB, Chung TS, Goh SH,
Leong KW (2005) Polyethylenimine-grafted multiwalled car-
bon nanotubes for secure noncovalent immobilization and
efficient delivery of DNA. Angew Chem Int Ed Engl
44:4782–4785
68 Z. Sun et al.
Luo Y, Wen YJ, Ding ZY, Fu CH, Wu Y, Liu JY, Li Q, He QM, Zhao
X, Jiang Y, Li J, Deng HX, Kang B, Mao YQ, Wei YQ (2006)
Immunotherapy of tumors with protein vaccine based on chicken
homologous Tie-2. Clin Cancer Res 12:1813–1819
Martin CR, Kohli P (2003) The emerging field of nanotube
biotechnology. Nat Rev Drug Discov 2:29–37
Mesa C, Fernandez LE (2004) Challenges facing adjuvants for cancer
immunotherapy. Immunol Cell Biol 82:644–650
Ni Y, Hu H, Malarkey EB, Zhao B, Montana V, Haddon RC, Parpura
V (2005) Chemically functionalized water soluble single-walled
carbon nanotubes modulate neurite outgrowth. J Nanosci Nano-
technol 5:1707–1712
Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber
JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994)
Treatment of 283 consecutive patients with metastatic melanoma
or renal cell cancer using high-dose bolus interleukin 2. Jama
271:907–913
Schirrmacher V (2005) Clinical trials of antitumor vaccination with an
autologous tumor cell vaccine modified by virus infection:
improvement of patient survival based on improved antitumor
immune memory. Cancer Immunol Immunother 54:587–598
Sun YP, Fu K, Lin Y, HuangW (2002) Functionalized carbon nanotubes:
properties and applications. Acc Chem Res 35:1096–1104
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T,
Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y,
Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical
recurrence rates of hepatocellular carcinoma: a randomised trial.
Lancet 356:802–807
Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R,
Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH,
Hanna MG Jr, Pinedo HM (1999) Active specific immunother-
apy for stage II and stage III human colon cancer: a randomised
trial. Lancet 353:345–350
Williams KA, Veenhuizen PT, de la Torre BG, Eritja R, Dekker C
(2002) Nanotechnology: carbon nanotubes with DNA recogni-
tion. Nature 420:761
Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004)
Vaccination with tumor lysate-pulsed dendritic cells elicits
antigen-specific, cytotoxic T-cells in patients with malignant
glioma. Cancer Res 64:4973–4979
Zanello LP, Zhao B, Hu H, Haddon RC (2006) Bone cell proliferation
on carbon nanotubes. Nano Lett 6:562–567
Aluminum nanoparticles enhance anticancer immune response 69
